Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model** Presented in part at the Annual Meeting of the Belgian Endocrine Society, Brussels, November 20, 1999 (Young Investigato

Brief coronary occlusion followed by reperfusion leads to reversible myocardial dysfunction (stunning) which can induce irreversible damage of other organ systems. We studied the effects of pretreatment with recombinant human GH (rhGH) and the GH-secretagogue GHRP-2 on myocardial stunning in a blood-perfused isolated rabbit heart model. In a first set of experiments, effects of bolus rhGH administration (3.5 mg/kg) (n = 5) into the aortic root of unpretreated animals were compared with those of saline (n = 6). In a second set, animals were pretreated for 14 days with SC rhGH 3.5 mg/kg·day (n = 9) or 160 μg/kg·day GHRP-2 (n = 8) in two divided doses. Body weight and plasma concentrations of rhGH, rabbit GH (rGH) and IGF-I were determined before and at the end of 14 days pretreatment. Hearts were excised and submitted to 15 min ischemia followed by 80 min reperfusion, after which postischemic recovery was compared with nonischemic hearts mounted into the same system. At study end, all hearts were snap-froze...

[1]  T. Hedner,et al.  The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats after Experimental Myocardial Infarction1. , 2000, Endocrinology.

[2]  M. Nishihara,et al.  Fas/Fas ligand system in prolactin-induced apoptosis in rat corpus luteum: possible role of luteal immune cells. , 1999, Biochemical and biophysical research communications.

[3]  M. Ashraf,et al.  Role of protein kinase C in mitochondrial KATP channel-mediated protection against Ca2+ overload injury in rat myocardium. , 1999, Circulation research.

[4]  R. Musters,et al.  PKC-dependent preconditioning with norepinephrine protects sarcoplasmic reticulum function in rat trabeculae following metabolic inhibition. , 1999, Journal of molecular and cellular cardiology.

[5]  E. Arvat,et al.  Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans , 1999, Journal of endocrinological investigation.

[6]  E. Marbán,et al.  Molecular and cellular mechanisms of myocardial stunning. , 1999, Physiological reviews.

[7]  P. Pagliaro,et al.  The effects of ischemic preconditioning on resting coronary flow and reactive hyperemia: involvement of A1 adenosine receptors. , 1999, Life sciences.

[8]  E. Lascano,et al.  Left ventricular regional systolic and diastolic function in conscious sheep undergoing ischemic preconditioning. , 1999, Cardiovascular research.

[9]  G. Heusch,et al.  AT1 receptor blockade in experimental myocardial ischemia/reperfusion , 2003, Basic Research in Cardiology.

[10]  M. Lomsky,et al.  A placebo-controlled study of growth hormone in patients with congestive heart failure. , 1998, European heart journal.

[11]  D. Griese,et al.  Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. , 1998, Cardiovascular research.

[12]  M. Bernareggi,et al.  Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. , 1998, Journal of cardiovascular pharmacology.

[13]  P. Poole‐Wilson,et al.  Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy , 1998, The Lancet.

[14]  T. Hedner,et al.  Growth hormone improves cardiac function in rats with experimental myocardial infarction , 1997, European journal of clinical investigation.

[15]  P. Douglas,et al.  Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. , 1997, Journal of the American College of Cardiology.

[16]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[17]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[18]  P. Douglas,et al.  Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. , 1996, Circulation.

[19]  C. Bowers,et al.  The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3',5'-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. , 1996, The Journal of endocrinology.

[20]  R. Clark,et al.  Beneficial Effects of Growth Hormone and Insulin‐Like Growth Factor‐1 in Experimental Heart Failure in Rats Treated with Chronic ACE Inhibition , 1995, Journal of cardiovascular pharmacology.

[21]  R. Clark,et al.  Growth hormone improves cardiac performance in experimental heart failure. , 1995, Circulation.

[22]  R. Mentzer,et al.  Salutary effects of exogenous adenosine administration on in vivo myocardial stunning. , 1995, The Journal of thoracic and cardiovascular surgery.

[23]  J. Ross,et al.  Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. , 1995, The Journal of clinical investigation.

[24]  R. Kloner,et al.  Reperfusion injury induces apoptosis in rabbit cardiomyocytes. , 1994, The Journal of clinical investigation.

[25]  P. Marzullo,et al.  Growth hormone and the heart , 2001, Endocrine Updates.

[26]  B. Hille,et al.  Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by two mechanisms. , 1994, Endocrinology.

[27]  K. Caidahl,et al.  Cardiovascular and renal effects of growth hormone * , 1994, Clinical endocrinology.

[28]  C. Carella,et al.  Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. , 1993, The Journal of clinical endocrinology and metabolism.

[29]  L. Saccá,et al.  Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. , 1993, The Journal of clinical endocrinology and metabolism.

[30]  M. Borgers,et al.  R56865, a Na(+)- and Ca(2+)-overload inhibitor, reduces myocardial ischemia-reperfusion injury in blood-perfused rabbit hearts. , 1993, Journal of molecular and cellular cardiology.

[31]  L. Becker,et al.  Relation between glycolysis and calcium homeostasis in postischemic myocardium. , 1992, Circulation research.

[32]  Y. Lecarpentier,et al.  Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. , 1990, The Journal of clinical investigation.

[33]  H. Orskov,et al.  Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study. , 1988, Danish medical bulletin.

[34]  J. Jansson,et al.  Growth hormone-releasing hormone. , 1986, Endocrine reviews.

[35]  F. Momany,et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.

[36]  P. D. de Moor,et al.  Heterogeneity of human growth hormone in serum. , 1974, Annales d'endocrinologie.

[37]  M. Beznák.  The restoration of cardiac hypertrophy and blood pressure in hypophysectomized rats by large doses of lyophilized anterior pituitary and growth hormone , 1954, Journal of Physiology.